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The therapeutic benefits of acupoint injection of vitamin K in spleen-6 (SP6) for the treat-
ment of primary dysmenorrhea have been observed in limited clinical settings. However,
menadione, the form of vitamin K most studied for treating dysmenorrhea, is not
routinely used in clinical practice in North America. As part of a larger clinical trial among
women aged 18e25 years with primary dysmenorrhea, we conducted a substudy to test
the plasma concentration of phylloquinone (vitamin K1). We collected blood samples from
four women before and 24e48 hours after an acupoint injection of phylloquinone in SP6.
Despite the rapid turnover of phylloquinone observed in previous studies, we found that
the plasma phylloquinone concentrations increased significantly from preinjection to 1e2
days after the injection. Interestingly, higher phylloquinone concentrations were corre-
lated with less pain intensity among women with dysmenorrhea. Additional research is
needed to understand the association between vitamin K and menstrual pain, including
the role of vitamin K deficiency in inflammation and pain, and on the possible mechanisms
of acupoint injection of vitamin K for the treatment of primary dysmenorrhea.ter for Integrative Medicine, University of California, UCSF Box Number 1726, San Francisco,
. Chao).
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Acupoint injection of vitamin K in spleen-6 (SP6) has been
used as an effective treatment for primary and secondary
dysmenorrhea and pelvic pain for the past three decades in
local clinical settings in China and Italy [1e4]. Therapeutic
benefits of this treatment are rapid pain relief within 30
minutes, less restriction in daily activities, reduced number
of hours in bed, and a decrease in pain medications used.
SP6 is a point frequently used for regulating the menstrual
cycle [5], but the use of vitamin K for menstrual conditions
is relatively uncommon. The vitamin K form studied to date
in terms of acupoint injection is menadione (vitamin K3),
also referred to as menadiol (vitamin K4) when injected in a
water-soluble form. Menadione is no longer used thera-
peutically in the United States due to concerns of liver
damage [6]. However, recent data suggest that menadione
is an intermediate in the conversion of the primary dietary
form phylloquinone (vitamin K1) to another form of vitamin
K, that is, menaquinone-4 [7]. In the United States, vitamin
K is administered in the form of phylloquinone to infants to
prevent hemorrhage and to adults in anticoagulant therapy
to reverse the effects of undercoagulation. The functions of
vitamin K beyond its role in coagulation are increasingly of
interest [8,9], but little is known about the potential
mechanism of vitamin K on menstrual pain. Previous
research suggests that vitamin K deficiency is associated
with menstrual disorders [10]. In addition, studies using
animal models indicate relaxation of the uterine muscle
spasm of rabbits and rats within 3e5 minutes of menadione
administration [11].
Plasma phylloquinone concentrations administered
orally or intravenously peak and return to close to baseline
levels, usually within 24 hours [12]. Intramuscular injection
of vitamin K may have a depot effect producing slow ab-
sorption from the site of injection [13]. This depot effect
may explain the prolonged benefits of acupoint injection
suggested by previous research [1], although menadione
would have a different pharmacokinetics compared with
phylloquinone based on differences in biochemical struc-
ture and depending on the solubility of the form injected.
To our knowledge, empirical evidence of plasma concen-
tration following acupoint injection of phylloquinone has
not been collected. To address this gap, we analyzed
plasma phylloquinone concentrations following acupoint
injection treatment among women with dysmenorrhea.
2. Materials and methods
All study procedures were approved by the University of
California, San Francisco (UCSF) Committee on Human
Research and the UCSF Clinical Research Center (CRC) and
registered in ClincalTrials.gov (NCT00995917). We con-
ducted a pilot clinical trial in the United States to assess the
acceptability, feasibility, and efficacy of acupoint injection
of phylloquinone in SP6 among young women with primary
dysmenorrhea. The study consisted of a randomized cross-
over pilot study comparing phylloquinone in SP6 with saline
in a nonacupuncture point [14]. Here we describe a sub-
study conducted to determine the plasma concentrations of
phylloquinone before and after acupoint injection.The detailed methodology has been described previously
[14]. Recruitment primarily occurred through outpatient
clinics at local community health centers in San Francisco.
Study staff prescreened prospective participants by tele-
phone based on the inclusion and exclusion criteria. We
consented and enrolled study participants who were
English-speaking young women, 18e25 years of age, and
with primary dysmenorrhea, which is defined as recurrent
painful periods not fully relieved by other treatments for at
least 6 months. We excluded women who had a history of
term pregnancy, abdominal surgery, pelvic inflammatory
disease or chlamydia; or those who were currently preg-
nant, diagnosed or suspected of acute and chronic condi-
tions, under concomitant therapy for acute or chronic pain,
using hormonal contraception, under treatment with anti-
coagulant drugs for any reason, intolerant to nonsteroidal
anti-inflammatory drugs or aspirin, having bleeding or
noncyclic pelvic pain, or dysmenorrhea due to any other
suspected or recognized causes. Diagnosis of primary
dysmenorrhea was confirmed by the nurse practitioner
based on history and physical examination. All consent,
screening, and study procedures were conducted at the
UCSF CRC. Participants were offered an incentive of $40 for
the injection visit, $30 for their first blood draw, and $50 for
their second blood draw.
Two nurse practitioners trained in acupoint injection
performed the study procedures. Injection treatment was
administered to study participants presenting with pain,
during the first 2 days of their menstrual cycle. Acupoint
injections were administered bilaterally in both legs in SP6,
located on the lower leg, three cun (the width of a person’s
thumb at the knuckle) proximal to the peak of the medial
malleolus. This area is just along the posterior aspect of
the tibial bone. The injected muscle was the soleus. The
nurse practitioner inserted a Number 23 gauge 2.5-cm long
needle into the point and 5 mg of phylloquinone/0.5 mL
volume was injected intramuscularly. The needle was
removed, and the point was patted with gauze pads if
bleeding was present. Consistent sourcing, quality, and
storage of phylloquinone were ensured by the UCSF Phar-
macy Services.2.1. Blood samples
To assess plasma phylloquinone concentration, each
participant had two blood samples drawn. The first blood
draw took place either immediately after the participant
consented to participate in the study, or at another
scheduled time before acupoint injection of phylloquinone
in SP6. The second blood draw took place 20e48 hours after
the acupoint injection treatment. Participants were
instructed to fast 12 hours before each blood draw. Nurses
at the CRC confirmed whether participants had fasted
based on verbal self-report and then drew 10 mL of blood
for each blood sample. The blood was spun and stored in a
freezer at 70 C at the CRC until shipped to the Vitamin K
Laboratory at the Jean Mayer United States Department of
Agriculture Human Nutrition Research Center on Aging at
Tufts University for analysis of phylloquinone content.
Plasma concentrations of phylloquinone were measured by
reverse-phase high-performance liquid chromatography,
Vitamin K1 and dysmenorrhea 153which has a lower limit of detection of 0.02 nmol/L for
phylloquinone [15].
2.2. Pain intensity
The study participants’ level of menstrual pain was
measured using an 11-point (0e10) Pain Intensity Numerical
Rating Scale (PI-NRS) [16]. At the injection visit, PI-NRS was
obtained immediately before injection of vitamin K1
(defined as baseline), and then 5, 15, 30, and 60 minutes
after the injection treatment. The difference in PI-NRS
from baseline to 60 minutes was used as the primary clin-
ical outcome in the study. At the consent visit and at
monthly follow ups, we obtained participants’ PI-NRS of
their worst pain from cramps during their last menstrual
period. We used paired Student t tests to assess the sta-
tistical difference of phylloquinone concentrations and
pain intensity before and after the acupoint injection. We
also assessed the correlation between worst pain intensity
from cramps during the most recent menstrual cycle and
phylloquinone using Pearson correlation.
3. Results
We recruited four women to participate in the substudy of
plasma phylloquinone concentration. All four participants
were non-Hispanic White and had obtained a college level
of education. Participants were on average 22 years of age
and had a current cycle length of 29 days. Average age of
menarche was 13 years.
All four participants had notable changes in plasma
phylloquinone concentrations from preinjection to post-
injection of phylloquinone. Analysis of plasma phylloqui-
none indicated nondetectable concentrations before
acupoint injection. By contrast, phylloquinone concentra-
tions ranged from 40 to 425 nmol/L, 20e48 hours following
the injection (Table 1).
On average, participants had a baseline pain intensity of
4.63 immediately before acupoint injection of phylloqui-
none in SP6. Sixty minutes following injection, average pain
intensity decreased to 1.75. This difference of 2.88 points
on the PI-NRS was statistically significant (p < 0.05). Par-
ticipants also reported the intensity of their worst pain
from cramps during their most recent menstrual cycle.
During the menstrual cycles when the first blood samplesTable 1 Plasma phylloquinone concentrations before and
after acupoint injection of phylloquinone in spleen-6.
Participant Phylloquinone
at baseline
(nmol/L)
Phylloquinone
after injection
(nmol/L)
Number of
hours after
injection blood
sample was
drawn
A ND 130 46
B ND 40 48
C ND 425 22
D ND 190 21
ND Z not detectable (<0.02 nmol/L).were drawn, participants’ worst pain was on average 8.38.
During the menstrual cycles of the second blood draws, in
which the acupoint injection of phylloquinone occurred,
participants’ worst pain was on average 4.50. In addition,
phylloquinone concentrations were negatively correlated
with the pain intensity of worst cramps during the most
recent menstrual cycle (r Z 0.59), with higher pain rat-
ings associated with lower concentrations of phylloquinone
(Figure 1). Because pain intensity varies with time, and
blood was sampled at various time points, these findings
are suggestive. Confirmation of these findings using a larger
clinical trial with multiple timed blood samples is required
before conclusions are drawn regarding the absolute
effectiveness of phylloquinone in reducing menstrual pain.4. Discussion
Our study findings provide evidence of an increased con-
centration of phylloquinone when injected at the
acupuncture point SP6. Vitamin K is typically studied in the
context of blood clotting and bone health although recent
emerging research suggests that vitamin K may have other
roles, including reproductive health [9]. Vitamin K therapy
may decrease the length of prolonged menstrual flow as a
result of its action on prothrombin, a vitamin K-dependent
coagulation protein produced in the liver [17]. The associ-
ation between the liver and menstrual flow is consistent
with traditional Chinese medicine (TCM) theory, which sees
the liver as a key organ in the physiology of menstruation,
and critical in moving blood and qi. From a TCM perspec-
tive, stagnation of liver qi or liver blood is a major cause of
painful periods [5]. The acupuncture point SP6 is commonly
used for menstrual conditions because it is a crossing point
of the liver, spleen, and kidney channels, which are
important in creating, storing, and moving blood [5].
Alternatively, vitamin K is being explored for its potential
role in reducing proinflammatory cytokines [8], which may
also contribute to the beneficial effects.
Our study is limited by the small sample size of only four
women and by the lack of a comparison group. Further-
more, the study design precludes drawing any causal in-
ferences from our data because pain intensity varies withFigure 1 Correlation between plasma phylloquinone con-
centrations and pain intensity during last menstrual cycle.
154 M.T. Chao et al.time, and blood samples were drawn at variable intervals
before and after the acupoint injection. Nonetheless, our
finding of high plasma phylloquinone concentrations after
intramuscular injection of vitamin K warrants additional
research on the extent of the synergistic action with the
site of injection, as suggested by previous studies of acu-
point injection [18,19]. In addition, our finding that phyl-
loquinone concentrations and pain intensity are correlated
warrants additional research to explore possible mecha-
nisms of acupoint injection of vitamin K and dysmenorrhea,
including the association between vitamin K deficiency and
dysmenorrhea, and the role of vitamin K and prostaglan-
dins, inflammation and pain.
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